Jennifer Tousignant Sells 14,212 Shares of Viridian Therapeutics (NASDAQ:VRDN) Stock

Viridian Therapeutics, Inc. (NASDAQ:VRDN) insider Jennifer Tousignant sold 14,212 shares of the business’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $24.50, for a total transaction of $348,194.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Viridian Therapeutics Trading Down 0.9%

Viridian Therapeutics stock opened at $24.29 on Friday. The business’s 50-day simple moving average is $19.82 and its 200-day simple moving average is $20.99. Viridian Therapeutics, Inc. has a 52 week low of $13.18 and a 52 week high of $34.29. The firm has a market capitalization of $2.75 billion, a PE ratio of -7.21 and a beta of 0.91. The company has a debt-to-equity ratio of 0.43, a quick ratio of 16.95 and a current ratio of 16.95.

Viridian Therapeutics (NASDAQ:VRDN) last released its earnings results on Thursday, August 6th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($1.03) by ($0.02). Viridian Therapeutics had a negative net margin of 505.86% and a negative return on equity of 72.97%. The company had revenue of $0.28 million for the quarter, compared to analyst estimates of $0.06 million. Equities research analysts forecast that Viridian Therapeutics, Inc. will post -4.07 earnings per share for the current year.

Institutional Trading of Viridian Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of VRDN. Vanguard Group Inc. raised its stake in shares of Viridian Therapeutics by 29.6% during the 4th quarter. Vanguard Group Inc. now owns 5,612,144 shares of the company’s stock worth $174,650,000 after purchasing an additional 1,280,161 shares in the last quarter. Commodore Capital LP raised its stake in Viridian Therapeutics by 35.4% in the 2nd quarter. Commodore Capital LP now owns 4,875,000 shares of the company’s stock valued at $68,152,000 after acquiring an additional 1,275,000 shares during the period. State Street Corp raised its stake in Viridian Therapeutics by 35.7% in the 4th quarter. State Street Corp now owns 3,466,560 shares of the company’s stock valued at $107,879,000 after acquiring an additional 912,394 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in Viridian Therapeutics by 42.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,439,414 shares of the company’s stock valued at $107,036,000 after purchasing an additional 1,021,310 shares during the last quarter. Finally, Wellington Management Group LLP lifted its holdings in Viridian Therapeutics by 1.6% during the 2nd quarter. Wellington Management Group LLP now owns 3,128,362 shares of the company’s stock valued at $57,468,000 after purchasing an additional 49,808 shares during the last quarter.

Analyst Upgrades and Downgrades

VRDN has been the subject of several recent analyst reports. Wells Fargo & Company raised shares of Viridian Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $20.00 to $31.00 in a report on Monday, June 29th. Evercore set a $26.00 target price on Viridian Therapeutics in a research report on Friday, May 15th. Weiss Ratings lowered shares of Viridian Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 30th. Royal Bank Of Canada increased their target price on Viridian Therapeutics from $35.00 to $36.00 and gave the company an “outperform” rating in a research note on Friday, August 7th. Finally, The Goldman Sachs Group reiterated a “buy” rating and issued a $39.00 target price on shares of Viridian Therapeutics in a report on Tuesday, June 30th. Thirteen equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $38.93.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.